Global digital biomarkers market will reach $22.54 billion by 2030, growing by 36.2% annually over 2020-2030 driven by rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare.

Highlighted with 91 tables and 99 figures, this 199-page report “Global Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure 

• Growth Drivers 

• Restraints and Challenges

• Emerging Product Trends & Market Opportunities

• Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Region. 

Based on System Component, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Data Collection Tools

• Digital Platforms

• Mobile Apps

• Desktop-based Software

• Wearables

• Biosensors

Data Integration Systems

Based on Therapeutic Area, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cardiovascular Diseases

Neurodegenerative Disorders

• Parkinson’s Disease

• Multiple Sclerosis

• Alzheimer’s Disease

Sleep and Movement Diseases

Psychiatric Disorders

Chronic Pain

Gastrointestinal Diseases

Diabetes

Respiratory Conditions

Other Diseases

Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Wellness

• Disease Diagnosis

• Personalised Medication

• Drug Discovery and Development

Based on Development Status, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Novel Digital Biomarkers

• Original Digital Biomarkers

• Approved Digital Biomarkers

Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. 

• Biopharmaceutical Companies & Labs

• Healthcare Providers

• Insurance Payers

Geographically, the following regions together with the listed national/local markets are fully investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

• Europe (Germany, UK, France, The Netherlands, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania)

• North America (U.S., Canada, and Mexico)

• South America (Brazil, Chile, Argentina, Rest of South America)

• RoW (Saudi Arabia, UAE, Israel)

For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in global digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request): 

Actigraph LLC

Akili Interactive Labs

AliveCor Inc

Altoida Inc

Amgen Inc

Bayer AG

Biogen Inc

Cambridge Cognition Plc

Eli Lilly and Company

Evidation Health, Inc.

F. Hoffmann-La Roche Ltd

Fitbit Inc

GlaxoSmithKline Plc

Happify Health

Human API

IXICO Plc

Koninklijke Philips N.V.

Medical Care Corporation

Medopad Ltd

Mindstrong Health

Neurotrack Technology, Inc

Novartis International AG

Pfizer Inc.

Quanterix Corporation

Sanofi S.A.

The Takeda Pharmaceuticals Company Limited

Verily Life Sciences

Winterlight Labs Inc.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)